- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03490864
Strengthening Circadian Signals
Strengthening Circadian Signals to Enhance Cardiometabolic Functions
There is a growing body of evidence from both laboratory and field studies that disrupted circadian function, particularly decreased amplitude and stability of rhythmic behaviors represent significant risk factors for cardiometabolic disease (CMD) in humans. The exciting evidence of the ubiquity of circadian clocks in all tissues and their critical role in metabolism, not only opens up new avenues for understanding the mechanistic interactions between central and peripheral clocks in cardiometabolic disease pathogenesis, but also to develop therapeutic interventions to re-establish synchrony between central and peripheral clocks with each other and with the external physical and social environments. Feeding has been shown to synchronize clocks in peripheral tissues. Animal studies have demonstrated that restricting feeding to the active period decreases CMD risk, while in humans decreased caloric intake in the evening is associated with a lower body mass index (BMI). The amplitude of melatonin can be considered a marker of robustness of central circadian function, but melatonin also has physiological effects beyond circadian regulation throughout the body. Recent observations have demonstrated that having a low melatonin level is a risk factor for incident diabetes and hypertension independent of sleep duration. Together, the evidence suggests that strategies aimed at synchronizing feeding behavior and enhancing the nocturnal melatonin signal can positively impact cardiometabolic function.
We propose to take an innovative approach that combines the recent data on the role of feed/fast patterns on clock regulated metabolic activity and the reemergence of scientific interest of the central and peripheral effects of melatonin on cardiometabolic function to elucidate the physiological and molecular mechanisms that underlie the relationship between circadian dysregulation and obesity associated CMD risk. This will be accomplished by strengthening the amplitude of circadian metabolic signals via meal timing and enhancement of nocturnal circadian signaling with exogenous melatonin in overweight and obese middle aged and older adults. In addition, this study will provide crucial information regarding the importance of circadian timing for the design of future clinical trials on CMD in overweight and obese adults. This is a critical time in the lifespan when circadian based strategies for prevention and treatment are most likely to have the greatest impact on CMD risk. This project will enroll 100 adults (40-54 years) to participate in a parallel (4 arm intervention) placebo controlled study to determine whether a six- week program of meal timing and/or low dose (1 mg) melatonin administration will enhance circadian amplitude and enhance cardiometabolic function, as well as to evaluate the potential beneficial effects of a regimen that combines both approaches. The results from this study will demonstrate novel mechanistically based approaches for maintaining and improving circadian-metabolic health during a critical time in the lifespan when there is a rapid increase in the prevalence of CMD.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Phyllis Zee, MD, PhD
- Phone Number: 3125034409
- Email: p-zee@northwestern.edu
Study Contact Backup
- Name: Kathryn Reid, PhD
- Phone Number: 3125031528
- Email: k-reid@northwestern.edu
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern University
-
Contact:
- Kathy Reid, PhD
- Phone Number: 312-503-1528
- Email: k-reid@northwestern.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults 35-54 years old.
- BMI ≥25 to <45
Regular eating schedule
- consuming at least 2 meals/day
Regular sleep schedules (deviation ≤2 hours in daily mid-sleep time)
- self-reported average sleep duration of ≥6.5 hours,
- habitual mid-sleep time 2-5am,
- habitual time in bed of ≤ 9 hours,
Habitual overnight fast of ≤ 13 hour
- Determined by a mean overnight fast ≤ 13 hours over 3 days of self-monitoring of food intake at screening
- HbA1C<6.5
Exclusion Criteria:
- History or current diagnosis of a primary sleep disorder (Chronic insomnia, restless leg syndrome, parasomnias, sleep apnea)
- AHI ≥30
- Current anemia
- Diagnosis of diabetes or currently on any medications for diabetes.
- Endocrine dysfunction including PCOS
- History of cognitive or other neurological disorders
- History of DSM-V criteria for any major psychiatric disorder
- Night Eating Syndrome (NES)
- Beck depression Index (BDI) of ≥16 indicating moderate depression
- Mini mental status Exam <26 indicating cognitive impairment.
- Unstable or serious medical conditions
- Individuals with pacemakers, defibrillators, mediation pumps, or any other implanted device.
- Any GI disease that requires dietary adjustment
- Current or use within last month of melatonin
- Current use of psychoactive, hypnotic, stimulants, or pain medications.
- Current use of hormone replacement therapy
- Shift work or other self-imposed irregular sleep schedules.
- History of habitual smoking (≥6 cigarettes/week)
- Caffeine consumption >400 mg/day
- Medically managed or self-reported weight loss program within past 6 months
- Bariatric weight loss surgery.
- Blindness or visual impairment other than glasses
- Allergic to heparin.
- Adults unable to consent will be excluded.
- Pregnant women will be excluded.
- Prisoners will be excluded.
- Individuals who are not yet adults (infants, children, teenagers) will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Meal timing + Melatonin
This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time.
This arm will also include a 1mg melatonin supplementation given daily during the intervention.
|
Melatonin (1mg) or placebo will be administered daily during the intervention.
Melatonin capsules will be obtained from Life Extension (Ft.
Lauderdale, FL).
The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical.
We have worked with this IDP on other projects.
The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
Subjects are instructed to maintain an extended overnight fasting period of 12-16 hours.
Other Names:
|
Experimental: Meal timing + Placebo
This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time.
This arm will also include a melatonin placebo (lactose) supplementation given daily during the intervention.
|
Subjects are instructed to maintain an extended overnight fasting period of 12-16 hours.
Other Names:
Melatonin (1mg) or placebo will be administered daily during the intervention.
Melatonin capsules will be obtained from Life Extension (Ft.
Lauderdale, FL).
The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical.
We have worked with this IDP on other projects.
The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
|
Experimental: Melatonin
This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake.
No extended overnight fasting will be imposed.
This arm will include a 1mg melatonin supplementation given daily during the intervention.
|
Melatonin (1mg) or placebo will be administered daily during the intervention.
Melatonin capsules will be obtained from Life Extension (Ft.
Lauderdale, FL).
The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical.
We have worked with this IDP on other projects.
The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
Subjects are instructed to maintain their habitual meal timing.
Other Names:
|
Placebo Comparator: Placebo
This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake.
No extended overnight fasting will be imposed.
This arm will also include a melatonin placebo (lactose) supplementation given daily during the intervention
|
Melatonin (1mg) or placebo will be administered daily during the intervention.
Melatonin capsules will be obtained from Life Extension (Ft.
Lauderdale, FL).
The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical.
We have worked with this IDP on other projects.
The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
Subjects are instructed to maintain their habitual meal timing.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Matsuda Index
Time Frame: 8 Weeks
|
The matsuda index of whole body index sensitivity will be calculated to explore the effect of sleep and circadian rhythms on the relationship between EOF, Melatonin, and CMD.
|
8 Weeks
|
Nocturnal Blood Pressure Dipping
Time Frame: 8 Weeks
|
Defined as a ratio of sleep Blood Pressure to wake Blood Pressure <0.90.
|
8 Weeks
|
Melatonin Amplitude
Time Frame: 8 Weeks.
|
The melatonin amplitude will be calculated to determine the effects of interventions on sleep and CMD outcomes.
|
8 Weeks.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Phyllis Zee, MD, PhD, Northwestern University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STU00206038
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Improving Cardiometabolic Outcomes in Adults
-
Northwestern UniversityRecruitingImproving Cardiometabolic Outcomes in Older AdultsUnited States
-
National University Hospital, SingaporeSingapore General HospitalCompletedCataract Surgery | Stress Levels | Music Improving Outcomes in Cataract SurgerySingapore
-
Chinese University of Hong KongCompletedPrimary Prevention | Cardiometabolic Disease | Health Coaching | Middle-aged AdultsHong Kong
-
Lakehead UniversityCanadian Institutes of Health Research (CIHR); Liberty Mutual Research Institute... and other collaboratorsUnknownWork Disability Reduction and Prevention | Improving Return-to-Work OutcomesCanada
-
Semey State Medical UniversityMinistry of Science and Higher Education of the Republic of KazakhstanRecruitingImproving the Early Diagnosis of Osteoporosis in Adults and Children Living in the Abay Region of KazakhstanKazakhstan
-
Nova Southeastern UniversityCompletedOlder Persons Interested in Improving Their Brain HealthUnited States
-
King Fahad Medical CityCompletedThe Study Focusses on Improving the Implantation Rate in IVFSaudi Arabia
-
University of MinnesotaCompletedChange in Dietary OutcomesUnited States
-
University of Alabama at BirminghamRecruitingCardiometabolic Risk Factors in Adult Wheelchair UsersUnited States
-
University of AarhusCompletedSubjective Discomfort | General Mucosal Irritation | Acute Changes in Respiratory Outcomes | Acute Changes in Cardiovascular Outcomes | Changes in BiomarkersDenmark
Clinical Trials on Melatonin 1 mg
-
Utrecht UniversityCompletedPharmacokinetics of MelatoninNetherlands
-
Ain Shams UniversityCompletedCerebral Palsy | Growth | Children, Only | MelatoninEgypt
-
Aragon Institute of Health SciencesMinisterio de Sanidad, Servicios Sociales e IgualdadUnknownSeptic Shock | Severe SepsisSpain
-
Khon Kaen UniversityUnknownPharmacokinetics of MelatoninThailand
-
Providence Health & ServicesCompletedRelapsing Remitting Multiple SclerosisUnited States
-
Khon Kaen UniversityThailand Research Fund; Srinagarind Hospital, Khon Kaen University; Khon Kaen... and other collaboratorsCompletedAdvanced Stage CancerThailand
-
Cairo UniversityCompleted
-
Lars Peter Holst AndersenUniversity of CopenhagenCompleted
-
Nalaka GooneratneNational Center for Complementary and Integrative Health (NCCIH)CompletedSleep Initiation and Maintenance DisordersUnited States
-
All India Institute of Medical Sciences, BhubaneswarCompleted